Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 2.42% on February 2, 2025, underperforming the CSI 300 index by 0.29 percentage points, ranking 16th among 31 sub-industries [4]. - Key performers in the sector included hospitals (-0.99%), pharmaceutical distribution (-1.63%), and blood products (-1.65%), while other biopharmaceuticals (-3.69%) and offline pharmacies (-3.09%) lagged behind [4]. - Elevar has submitted a New Drug Application (NDA) to the FDA for Lirafugratinib, a selective oral FGFR2 inhibitor, showing a 46.5% objective response rate (ORR) in clinical trials for cholangiocarcinoma patients [5]. - The disease control rate for Lirafugratinib reached 96.5%, with a median progression-free survival (PFS) of 11.3 months and a median overall survival (OS) of 22.8 months [5]. - Jichuan Pharmaceutical has signed an exclusive commercialization agreement for a nasal spray in Greater China, with a payment of up to 100 million RMB [5]. - Heng Rui Pharmaceutical received FDA acceptance for its BLA submission for a combination therapy for liver cancer [6]. - Shanghai Yizhong reported a projected revenue of 317 million RMB for 2025, reflecting an 82.72% year-on-year growth [6]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3].

Group 1 - Core viewpoint: Companies are announcing significant financial updates, including profit changes, new product approvals, and share repurchase plans [1][2][3][4][5][6][15] Group 2 - Company: Chip导科技 reported a revenue of 394 million yuan for 2025, a year-on-year increase of 11.52%, but a net profit of 106 million yuan, down 4.91% [1] - Company: 亿帆医药's subsidiary received a drug registration certificate for Vitamin K1 injection, which is used for treating vitamin K deficiency [2] - Company: 勤上股份 announced the termination of its share repurchase plan to stabilize stock prices [3] - Company: 极米科技 plans to repurchase shares worth between 50 million and 100 million yuan for employee stock ownership plans [4] - Company: 凌云光 intends to change the purpose of repurchased shares to cancellation, reducing total share capital from 461 million to 457 million shares [5] - Company: 苏州科达's general manager resigned, and the chairman will take over the role to ensure management continuity [6] - Company: 银轮股份 identified 徐铮铮 as a co-actual controller, following a retrospective recognition [7] - Company: 西南证券 received approval to issue bonds up to 14 billion yuan [8] - Company: 上港集团 expects a 1.3% year-on-year increase in container throughput for January [10] - Company: 宁波富达 plans to distribute a cash dividend of 0.7 yuan per 10 shares, totaling 101 million yuan [11] - Company: 协和电子 is investing 5 million yuan in a venture capital fund to enhance its understanding of high-tech industries [12] - Company: 乐鑫科技's controlling shareholder proposed a share repurchase plan of 50 million to 100 million yuan [13] - Company: 奥瑞德's subsidiary plans to invest approximately 145 million yuan in computing power equipment [14] - Company: 上汽集团 reported a 23.94% year-on-year increase in vehicle sales for January [15] - Company: 道恩股份 plans to acquire a foreign company's plastic business for 15.737 million USD [16] - Company: 红相股份 intends to transfer 100% equity of 南通瀚蓝 for 120 million yuan [17] - Company: 长龄液压 announced a tender offer to acquire 12% of its shares at 35.82 yuan per share [19] - Company: 润都股份 faces uncertainty regarding the approval of its innovative drug [20] - Company: *ST东易's asset injection plans face significant uncertainty [21] - Company: 棒杰股份 is undergoing a restructuring process that could improve its financial structure [22] - Company: 绿联科技 has submitted an application for H-share listing in Hong Kong [23] - Company: ST泉为 is facing a creditor's application for restructuring [24] - Company: 海思科's shareholders plan to reduce their holdings by up to 0.89% [25] - Company: 钧崴电子's shareholder plans to reduce holdings by up to 3% [26]

Group 1 - Far East Holdings announced that its subsidiary won a contract order worth 3.075 billion yuan, including contracts for green building cables and smart manufacturing cables [1] - Yifan Pharmaceutical received a drug registration certificate for Vitamin K1 injection, which is used to treat vitamin K deficiency-related bleeding [2] - Guangdong Electric Power A's Maoming Bohua Power Plant's Unit 4 has successfully commenced commercial operation, with a total investment of 7.484 billion yuan and an expected annual power generation of 8.6 billion kWh [4] Group 2 - Longfly Fiber reported that the global fiber optic cable industry market environment is normal, with product price fluctuations needing comprehensive assessment [25] - Shanghai Yizhong's net profit for 2025 increased by 819.42%, with total revenue of 317 million yuan, a growth of 82.72% [22] - Guizhou Power's subsidiary received a government subsidy of 200 million yuan [8] Group 3 - Zhongxing Communications plans to invest 117 million yuan in the Jianxing Zhanlu Fund, which focuses on new information technology and advanced manufacturing [10] - Suwen Electric Power's subsidiary established a joint investment fund with a total commitment of 68.5 million yuan, with Suwen contributing 5 million yuan [26] - ST Kaiyuan announced that its stock may face delisting risk due to expected negative net assets for 2025 [27]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for Vitamin K1 injection from the National Medical Products Administration on January 5, 2026, indicating a significant milestone in its product development [1] Group 1 - The Vitamin K1 injection is intended for the prevention and treatment of vitamin K deficiency bleeding in infants [1] - The company has invested approximately 20.66 million yuan in the research and development of the Vitamin K1 injection as of the date of the report [1]

Market Overview - A total of 70 stocks hit the daily limit up in the A-share market, with 53 stocks hitting the limit after excluding 17 ST stocks, resulting in an overall limit-up rate of 78.65% [1] Top Performers - Zhongheng Group had the highest limit-up order volume at 513,300 hands, followed by Ma Steel, Zhongtai Automobile, and Shandong Molong with order volumes of 304,400 hands, 272,100 hands, and 245,600 hands respectively [2] - Zhongheng Group announced that its wholly-owned subsidiary plans to acquire a patent for a drug technology (LZ-01) for treating chronic heart failure, which shows significant therapeutic advantages [2] Continuous Limit-Up Stocks - *ST Yazhen achieved 5 consecutive limit-ups, while Beijiajie and Wenke Co. had 4 consecutive limit-ups. Several other stocks, including *ST Yanshi and *ST Yushun, recorded 3 consecutive limit-ups [2] Sector Highlights Robotics - Multiple stocks in the robotics sector hit the limit-up, including Dongjie Intelligent, Furi Electronics, Guoji Precision, and others. Dongjie Intelligent is focusing on industrial intelligent logistics robots to create smart factories [4][7] eSIM Technology - Stocks such as Rihai Intelligent, Dongxin Peace, and Chengtian Weiye saw limit-ups, with Rihai Intelligent's SIM7070 series NB-IoT module being highlighted for its eSIM remote management capabilities [4][5][6] Pharmaceuticals - Pharmaceutical stocks like Chengyi Pharmaceutical, Zhongheng Group, Kehua Bio, and Guilin Sanjin also hit the limit-up. Chengyi Pharmaceutical's products have won bids in multiple provincial administrative regions [9] Institutional and Retail Activity - The net selling of Shanhai Intelligent exceeded 100 million yuan, while Dongxin Peace, Innovation Medical, and Aerospace Science and Technology were the top net buying stocks [10][11] - Institutional net buying was led by Dongjie Intelligent, Xinhan New Materials, and Beifang Changlong, with amounts of 209 million yuan, 84.8 million yuan, and 52 million yuan respectively [12] ETF Performance - The Food and Beverage ETF saw a slight decline of 0.52% over the past five days, with a net inflow of 10.56 million yuan [16] - The Gaming ETF increased by 3.12%, with a net inflow of 290 million yuan [16] - The Cloud Computing 50 ETF experienced a minor decline of 0.15%, with a net outflow of 1.24 million yuan [17]